

Giuseppe Bruno

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/932527/publications.pdf>

Version: 2024-02-01

93
papers

2,729
citations

147801

31
h-index

214800

47
g-index

94
all docs

94
docs citations

94
times ranked

4434
citing authors

#	ARTICLE	IF	CITATIONS
1	Facing Dementia During the COVID-19 Outbreak. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 1673-1676.	2.6	143
2	The GERAS Study: A Prospective Observational Study of Costs and Resource Use in Community Dwellers with Alzheimer's Disease in Three European Countries – Study Design and Baseline Findings. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 385-399.	2.6	129
3	Spontaneous Reversion of Mild Cognitive Impairment to Normal Cognition: A Systematic Review of Literature and Meta-Analysis. <i>Journal of the American Medical Directors Association</i> , 2016, 17, 943-948.	2.5	128
4	A case-control study on Alzheimer's disease and exposure to anesthesia. <i>Neurological Sciences</i> , 2002, 23, 11-14.	1.9	116
5	Autosomal Dominant Frontotemporal Lobar Degeneration Due to the C9ORF72 Hexanucleotide Repeat Expansion: Late-Onset Psychotic Clinical Presentation. <i>Biological Psychiatry</i> , 2013, 74, 384-391.	1.3	105
6	Muscarinic Agonist Therapy of Alzheimer's Disease. <i>Archives of Neurology</i> , 1986, 43, 659.	4.5	91
7	Behavioral and psychological subsyndromes in Alzheimer's disease using the Neuropsychiatric Inventory. <i>International Journal of Geriatric Psychiatry</i> , 2013, 28, 795-803.	2.7	86
8	Sex and gender differences in the treatment of Alzheimer's disease: A systematic review of randomized controlled trials. <i>Pharmacological Research</i> , 2017, 115, 218-223.	7.1	80
9	Caregiver Burden in Alzheimer's Disease: Differential Associations in Adult-Child and Spousal Caregivers in the GERAS Observational Study. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014, 4, 51-64.	1.3	77
10	Analysis of burden in caregivers of people with Alzheimer's disease using self-report and supervision hours. <i>Journal of Nutrition, Health and Aging</i> , 2014, 18, 677-684.	3.3	76
11	Determinants of societal costs in Alzheimer's disease: GERAS study baseline results. <i>Alzheimer's and Dementia</i> , 2015, 11, 933-945.	0.8	62
12	Buspiron, Parkinson's Disease, and the Locus Coeruleus. <i>Clinical Neuropharmacology</i> , 1986, 9, 373-378.	0.7	58
13	Reduced density of dopamine D2-like receptors on peripheral blood lymphocytes in Alzheimer's disease. <i>Mechanisms of Ageing and Development</i> , 2000, 120, 65-75.	4.6	57
14	Nutrition and Dementia: Evidence for Preventive Approaches?. <i>Nutrients</i> , 2016, 8, 144.	4.1	57
15	Sundowning in Dementia: Clinical Relevance, Pathophysiological Determinants, and Therapeutic Approaches. <i>Frontiers in Medicine</i> , 2016, 3, 73.	2.6	56
16	Causes of cross-over in unilateral neglect: between-group comparisons, within-patient dissociations and eye movements. <i>Brain</i> , 2005, 128, 1386-1406.	7.6	50
17	Effect of citalopram in treating hypersexuality in an Alzheimer's Disease case. <i>Neurological Sciences</i> , 2008, 29, 269-270.	1.9	49
18	Race reporting and disparities in clinical trials on Alzheimer's disease: A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 101, 122-128.	6.1	44

#	ARTICLE	IF	CITATIONS
19	Pharmacogenomics in Alzheimer's disease: a genome-wide association study of response to cholinesterase inhibitors. <i>Neurobiology of Aging</i> , 2013, 34, 1711.e7-1711.e13.	3.1	43
20	Circulating miR-127-3p as a Potential Biomarker for Differential Diagnosis in Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 455-464.	2.6	43
21	A pilot study on the use of interferon beta-1a in early Alzheimer's disease subjects. <i>Journal of Neuroinflammation</i> , 2014, 11, 30.	7.2	42
22	Modulation of the Cannabinoid System: A New Perspective for the Treatment of the Alzheimer's Disease. <i>Current Neuropharmacology</i> , 2019, 17, 176-183.	2.9	42
23	GABA-Agonist Therapy for Alzheimer's Disease. <i>Clinical Neuropharmacology</i> , 1986, 9, 257-263.	0.7	40
24	Cognitive reserve and the risk for Alzheimer's disease: a longitudinal study. <i>Neurobiology of Aging</i> , 2015, 36, 592-600.	3.1	38
25	Familial Alzheimer's disease sustained by presenilin 2 mutations: Systematic review of literature and genotype-phenotype correlation. <i>Neuroscience and Biobehavioral Reviews</i> , 2014, 42, 170-179.	6.1	37
26	Disease Progression in Mild Dementia due to Alzheimer Disease in an 18-Month Observational Study (GERAS): The Impact on Costs and Caregiver Outcomes. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2017, 7, 87-100.	1.3	36
27	Replication Study to Confirm the Role of CYP2D6 Polymorphism rs1080985 on Donepezil Efficacy in Alzheimer's Disease Patients. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 745-749.	2.6	35
28	Impact of behavioral subsyndromes on cognitive decline in Alzheimer's disease: data from the ICTUS study. <i>Journal of Neurology</i> , 2013, 260, 1859-1865.	3.6	35
29	Identifying factors of activities of daily living important for cost and caregiver outcomes in Alzheimer's disease. <i>International Psychogeriatrics</i> , 2016, 28, 247-259.	1.0	35
30	Providing Simultaneous COVID-19-sensitive and Dementia-Sensitive Care as We Transition from Crisis Care to Ongoing Care. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 968-969.	2.5	35
31	Cessation versus Continuation of Galantamine Treatment after 12 Months of Therapy in Patients with Alzheimer's Disease: A Randomized, Double Blind, Placebo Controlled Withdrawal Trial. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 211-220.	2.6	32
32	Plasma microRNA profiling distinguishes patients with frontotemporal dementia from healthy subjects. <i>Neurobiology of Aging</i> , 2019, 84, 240.e1-240.e12.	3.1	32
33	Promoting the Assessment of Frailty in the Clinical Approach to Cognitive Disorders. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 36.	3.4	30
34	How useful is the EQ-5D in assessing the impact of caring for people with Alzheimer's disease?. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 16.	2.4	27
35	Estimating dementia cases amongst migrants living in Europe. <i>European Journal of Neurology</i> , 2019, 26, 1191-1199.	3.3	27
36	Serotonin toxicity: a short review of the literature and two case reports involving Citalopram. <i>Neurological Sciences</i> , 2011, 32, 507-509.	1.9	26

#	ARTICLE	IF	CITATIONS
37	Determinants of time to institutionalisation and related healthcare and societal costs in a community-based cohort of patients with Alzheimer's disease dementia. <i>European Journal of Health Economics</i> , 2019, 20, 343-355.	2.8	26
38	Biomarkers and phenotypic expression in Alzheimer's disease: exploring the contribution of frailty in the Alzheimer's Disease Neuroimaging Initiative. <i>GeroScience</i> , 2021, 43, 1039-1051.	4.6	25
39	What Drives Country Differences in Cost of Alzheimer's Disease? An Explanation from Resource Use in the GERAS Study. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 797-812.	2.6	23
40	A descriptive study on constructional impairment in frontotemporal dementia and Alzheimer's disease. <i>European Journal of Neurology</i> , 2008, 15, 589-597.	3.3	21
41	The Impact of Frailty on the Risk of Conversion from Mild Cognitive Impairment to Alzheimer's Disease: Evidences from a 5-Year Observational Study. <i>Frontiers in Medicine</i> , 2017, 4, 178.	2.6	21
42	Progression of Extrapyrarnidal Signs in Alzheimer's Disease: Clinical and Neuropathological Correlates. <i>Journal of Alzheimer's Disease</i> , 2016, 49, 1085-1093.	2.6	20
43	From Evidence to Action: Promoting a Multidimensional Approach to Mild Cognitive Impairment. <i>Journal of the American Medical Directors Association</i> , 2015, 16, 710-711.	2.5	20
44	Frailty Index as a clinical measure of biological age in psychiatry. <i>Journal of Affective Disorders</i> , 2020, 268, 183-187.	4.1	20
45	A Novel Mutation in the Predicted TMIII Domain of the PSEN2 Gene in an Italian Pedigree with Atypical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 43-47.	2.6	19
46	Cognitive Interventions Targeting Subjective Cognitive Complaints. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2013, 28, 560-567.	1.9	19
47	External Validity of Randomized Controlled Trials on Alzheimer's Disease: The Biases of Frailty and Biological Aging. <i>Frontiers in Neurology</i> , 2017, 8, 628.	2.4	19
48	Restless Legs Syndrome in a Group of Patients With Alzheimer's Disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2013, 28, 165-170.	1.9	18
49	Gender Effects on Plasma PGRN Levels in Patients with Alzheimer's Disease: A Preliminary Study. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 313-318.	2.6	17
50	Predicting the Rate of Cognitive Decline in Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2016, 30, 237-242.	1.3	17
51	Issues about the use of subjective cognitive decline in Alzheimer's disease research. <i>Alzheimer's and Dementia</i> , 2014, 10, 881-882.	0.8	16
52	PRNP P39L Variant is a Rare Cause of Frontotemporal Dementia in Italian Population. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 353-357.	2.6	15
53	Contribution of right hemisphere to visual imagery: A visual working memory impairment?. <i>Journal of the International Neuropsychological Society</i> , 2008, 14, 902-911.	1.8	14
54	Prosodic Impairment in Alzheimer's Disease: Assessment and Clinical Relevance. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2011, 23, E21-E23.	1.8	14

#	ARTICLE	IF	CITATIONS
55	Rivastigmine in the Treatment of Hypersexuality in Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2013, 27, 287-288.	1.3	14
56	SORL1 Gene is Associated with the Conversion from Mild Cognitive Impairment to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 771-776.	2.6	14
57	Mild behavioral impairment: Ethical, methodological and clinical reflections. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 69, 402-403.	6.1	14
58	Bilateral simultaneous cerebellar infarction in the medial branches of the posterior inferior cerebellar artery territories. <i>Italian Journal of Neurological Sciences</i> , 1996, 17, 433-436.	0.1	13
59	The London APP Mutation (Val717Ile) Associated with Early Shifting Abilities and Behavioral Changes in Two Italian Families with Early-Onset Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 29, 484-490.	1.5	13
60	Neuropsychological predictors of rapidly progressive Alzheimer's disease. <i>Acta Neurologica Scandinavica</i> , 2015, 132, 417-422.	2.1	13
61	How to deal with missing longitudinal data in cost of illness analysis in Alzheimer's disease? suggestions from the GERAS observational study. <i>BMC Medical Research Methodology</i> , 2016, 16, 83.	3.1	13
62	Spontaneous Reversion of Clinical Conditions Measuring the Risk Profile of the Individual: From Frailty to Mild Cognitive Impairment. <i>Frontiers in Medicine</i> , 2017, 4, 184.	2.6	13
63	Operationalization of a frailty index in patients with multiple sclerosis: A cross-sectional investigation. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1939-1947.	3.0	13
64	Are we really tackling the "evidence-based medicine issue" in Alzheimer's disease?. <i>European Journal of Internal Medicine</i> , 2016, 35, e29-e30.	2.2	11
65	Inappropriate Sexual Behaviors Among Community-Dwelling Patients with Dementia. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 365-371.	1.2	11
66	The sterile controversy on the amyloid cascade hypothesis. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 83, 472-473.	6.1	11
67	Role of frailty in the assessment of cognitive functioning. <i>Mechanisms of Ageing and Development</i> , 2019, 181, 42-46.	4.6	9
68	Use of Biomarkers in Ongoing Research Protocols on Alzheimer's Disease. <i>Journal of Personalized Medicine</i> , 2020, 10, 68.	2.5	9
69	Analysis of burden in caregivers of people with Alzheimer's disease using self-report and supervision hours. <i>Journal of Nutrition, Health and Aging</i> , 0, , .	3.3	9
70	Need to Recalibrate Research Outcomes in Alzheimer's Disease: Focus on Neuropsychiatric Symptoms. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 2071-2073.	2.6	8
71	Regional Strength of Large-Scale Functional Brain Networks is Associated with Regional Volumes in Older Adults and in Alzheimer's Disease. <i>Brain Connectivity</i> , 2021, 11, 201-212.	1.7	8
72	Increased levels of acute-phase inflammatory proteins in plasma of patients with sporadic CJD. <i>Neurology</i> , 2012, 79, 1012-1018.	1.1	7

#	ARTICLE	IF	CITATIONS
73	Migrants seeking help for cognitive disturbances: exploratory data from an Italian memory clinic. <i>Neurological Sciences</i> , 2019, 40, 857-859.	1.9	7
74	The role of frailty in Parkinson's disease: a cross-sectional study. <i>Journal of Neurology</i> , 2022, 269, 3006-3014.	3.6	7
75	Presenilin 2 mutation R71W in an Italian early-onset sporadic Alzheimer's disease case. <i>Journal of Neurology</i> , 2011, 258, 2043-2047.	3.6	6
76	Position paper of the Italian Society for the study of Dementias (Sindem) on the proposal of a new Lexicon on Alzheimer disease. <i>Neurological Sciences</i> , 2012, 33, 201-208.	1.9	6
77	Estimating dementia cases in the immigrant population living in Italy. <i>Neurological Sciences</i> , 2018, 39, 1775-1778.	1.9	6
78	Counting deficits or diseases? The agreement between frailty and multimorbidity in subjects with cognitive disturbances. <i>Aging Clinical and Experimental Research</i> , 2020, 32, 179-182.	2.9	6
79	Activation of Tyrosine Phosphorylation Signaling in Erythrocytes of Patients with Alzheimer's Disease. <i>Neuroscience</i> , 2020, 433, 36-41.	2.3	6
80	Caerulein Treatment of Parkinson's Disease. <i>Clinical Neuropharmacology</i> , 1985, 8, 266-270.	0.7	5
81	Efficacy of sertraline in a patient with Neuro-Behçet's disease. <i>Journal of Clinical Neuroscience</i> , 2013, 20, 896-897.	1.5	4
82	Parkinson's disease among migrants in Europe: estimating the magnitude of an emerging phenomenon. <i>Journal of Neurology</i> , 2019, 266, 1120-1126.	3.6	4
83	Sociodemographic and Clinical Changes Over Time of Individuals Evaluated for Cognitive Disturbances: Good or Bad News?. <i>Journal of the American Medical Directors Association</i> , 2015, 16, 1095-1096.	2.5	2
84	Binge eating and fast cognitive worsening in an early-onset bvFTD patient carrying C9ORF72 expansion. <i>Neurocase</i> , 2015, 21, 543-547.	0.6	2
85	Mining clinical and laboratory data of neurodegenerative diseases by Machine Learning: transcriptomic biomarkers. , 2018, , ,		2
86	The Pipeline of Therapeutics Testing During the Emergency Phase of the COVID-19 Outbreak. <i>Frontiers in Medicine</i> , 2020, 7, 552991.	2.6	2
87	Supporting and Protecting People with Dementia in the COVID-19 Pandemic. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 43-49.	2.6	2
88	Prevalence and Safety of COVID-19 Vaccination in Community-Dwelling People with Dementia: Findings from a Tertiary Memory Clinic in Italy. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 1467-1474.	2.6	2
89	Why Mild Cognitive Impairment Should Not Be Approached as a Disease: Reply to Iraqi and Hughes. <i>Journal of the American Medical Directors Association</i> , 2017, 18, 273-274.	2.5	1
90	Baseline assessment of physical frailty in neurological drug development. <i>CNS Neuroscience and Therapeutics</i> , 2018, 24, 1309-1310.	3.9	1

#	ARTICLE	IF	CITATIONS
91	Agreement between diseases-centered and multidimensional models of care in disadvantaged settings. European Journal of Internal Medicine, 2018, 52, e32-e34.	2.2	0
92	Mediterranean Diet and Dementia. , 2018, , 103-115.		0
93	SAT0180â€¦EVALUATION OF FRAILTY IN SJÄ–GRENâ€™MS SYNDROME: CREATION OF A FRAILTY INDEX. , 2019, , .		0